Neopterin is Associated with Cardiovascular Events and All-cause Mortality in Renal Transplant Patients

Overview

Journal Clin Transplant

Specialty General Surgery

Date 2013 Dec 31

PMID 24372612

Citations 3

Authors

Hege Pihlstrom

Geir Mjoen

Winfried Marz

Dag Olav Dahle

Sadollah Abedini

Ingar Holme

Bengt Fellstrom

Alan Jardine

Stefan Pilz

Hallvard Holdaaas

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory markers show significant associations with cardiovascular events and all-cause mortality after kidney transplantation. Neopterin, reflecting interferon-γ-release, may better reflect the proinflammatory state of recipients than less specific markers.

Methods: Kidney transplant recipients in the Assessment of LEscol in Renal Transplant (ALERT) trial were examined and investigated for an association between serum neopterin and subsequent clinical events: graft loss, major cardiovascular events (MACE) and all-cause mortality.

Results: After adjustment for established and emerging risk factors neopterin expressed as neopterin-to-creatinine ratio was significantly associated with MACE (p = 0.009) and all-cause mortality (p = 0.002). Endpoints were more frequent with increasing quartiles of neopterin-to-creatinine ratio. The incidence rates of MACE and all-cause mortality were significantly increased in the upper quartiles compared with the first.

Conclusions: This long-term prospective analysis in stable kidney allograft recipients suggests that neopterin is associated with long-term risk of cardiovascular events and all-cause mortality, but not renal outcomes.

Citing Articles

GDF15, EGF, and Neopterin in Assessing Progression of Pediatric Chronic Kidney Disease Using Artificial Intelligence Tools-A Pilot Study.

Musial K, Stojanowski J, Bargenda-Lange A, Golebiowski T Int J Mol Sci. 2025; 26(5).

PMID: 40076962 PMC: 11899747. DOI: 10.3390/ijms26052344.

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients.

Pihlstrom H, Ueland T, Michelsen A, Aukrust P, Gatti F, Hammarstrom C PLoS One. 2020; 15(12):e0243759.

PMID: 33326471 PMC: 7743930. DOI: 10.1371/journal.pone.0243759.

Clinical Significance of Increased Serum Neopterin in Chronic Kidney Failure as a Biomarker of Cell-mediated Immunity.

Unuvar S, Aslanhan H J Med Biochem. 2019; 38(1):1-5.

PMID: 30820177 PMC: 6298458. DOI: 10.2478/jomb-2018-0019.

Plasma Biomarkers of Inflammation, the Kynurenine Pathway, and Risks of All-Cause, Cancer, and Cardiovascular Disease Mortality: The Hordaland Health Study.

Zuo H, Ueland P, Ulvik A, Eussen S, Vollset S, Nygard O Am J Epidemiol. 2016; 183(4):249-58.

PMID: 26823439 PMC: 4753283. DOI: 10.1093/aje/kwv242.

References

Huber C, Batchelor J, Fuchs D, Hausen A, Lang A, Niederwieser D . Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984; 160(1):310-6. PMC: 2187425. DOI: 10.1084/jem.160.1.310. View

Turkmen K, Tonbul H, Toker A, Gaipov A, Erdur F, Cicekler H . The relationship between oxidative stress, inflammation, and atherosclerosis in renal transplant and end-stage renal disease patients. Ren Fail. 2012; 34(10):1229-37. DOI: 10.3109/0886022X.2012.723580. View

Schennach H, Murr C, Gachter E, Mayersbach P, Schonitzer D, Fuchs D . Factors influencing serum neopterin concentrations in a population of blood donors. Clin Chem. 2002; 48(4):643-5. View

Grebe S, Kuhlmann U, Fogl D, Luyckx V, Mueller T . Macrophage activation is associated with poorer long-term outcomes in renal transplant patients. Clin Transplant. 2010; 25(5):744-54. DOI: 10.1111/j.1399-0012.2010.01345.x. View

Heeger P, Dinavahi R . Transplant immunology for non-immunologist. Mt Sinai J Med. 2012; 79(3):376-87. DOI: 10.1002/msj.21314. View

Spencer M, Jain A, Matteini A, Beamer B, Wang N, Leng S . Serum levels of the immune activation marker neopterin change with age and gender and are modified by race, BMI, and percentage of body fat. J Gerontol A Biol Sci Med Sci. 2010; 65(8):858-65. PMC: 2903784. DOI: 10.1093/gerona/glq066. View

Dahle D, Mjoen G, Oqvist B, Scharnagl H, Weihrauch G, Grammer T . Inflammation-associated graft loss in renal transplant recipients. Nephrol Dial Transplant. 2011; 26(11):3756-61. DOI: 10.1093/ndt/gfr163. View

Weimer R, Susal C, Yildiz S, Staak A, Pelzl S, Renner F . Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant. 2006; 6(8):1865-74. DOI: 10.1111/j.1600-6143.2006.01407.x. View

Chin G, Adams C, Carey B, Shaw S, Tse W, Kaminski E . The value of serum neopterin, interferon-gamma levels and interleukin-12B polymorphisms in predicting acute renal allograft rejection. Clin Exp Immunol. 2008; 152(2):239-44. PMC: 2384097. DOI: 10.1111/j.1365-2249.2008.03632.x. View

10.

Hoffmann G, Wirleitner B, Fuchs D . Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res. 2003; 52(8):313-21. DOI: 10.1007/s00011-003-1181-9. View

11.

Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson A, Pedersen T . Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005; 5(12):2929-36. DOI: 10.1111/j.1600-6143.2005.01105.x. View

12.

Schafer A, Daniel V, Dreikorn K, Opelz G . Assessment of plasma neopterin in clinical kidney transplantation. Transplantation. 1986; 41(4):454-9. DOI: 10.1097/00007890-198604000-00008. View

13.

Holdaas H, Fellstrom B, Jardine A, Holme I, Nyberg G, Fauchald P . Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361(9374):2024-31. DOI: 10.1016/S0140-6736(03)13638-0. View

14.

Estevez-Loureiro R, Recio-Mayoral A, Sieira-Rodriguez-Moret J, Trallero-Araguas E, Kaski J . Neopterin levels and left ventricular dysfunction in patients with chronic stable angina pectoris. Atherosclerosis. 2009; 207(2):514-8. DOI: 10.1016/j.atherosclerosis.2009.04.032. View

15.

Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D . Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem. 2010; 17(36):4511-20. DOI: 10.2174/092986710794183006. View

16.

Svensson M, Dahle D, Mjoen G, Weihrauch G, Scharnagl H, Dobnig H . Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol Dial Transplant. 2011; 27(6):2571-5. DOI: 10.1093/ndt/gfr694. View

17.

Abedini S, Holme I, Marz W, Weihrauch G, Fellstrom B, Jardine A . Inflammation in renal transplantation. Clin J Am Soc Nephrol. 2009; 4(7):1246-54. PMC: 2709521. DOI: 10.2215/CJN.00930209. View

18.

Roodnat J, Mulder P, Rischen-Vos J, van Riemsdijk I, van Gelder T, Zietse R . Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation. 2001; 72(3):438-44. DOI: 10.1097/00007890-200108150-00014. View

19.

Grebe S, Mueller T . Immune monitoring in organ transplantation using neopterin. Curr Drug Metab. 2002; 3(2):189-202. DOI: 10.2174/1389200024605109. View

20.

Avci E, Coskun S, Cakir E, Kurt Y, Akgul E, Bilgi C . Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients. Ren Fail. 2008; 30(8):784-90. DOI: 10.1080/08860220802249009. View